AGLE News and Press, Aeglea BioTherapeutics Inc. From 11/04/21

Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights PEACE baseline data at upcoming medical meeting underscore disease severity and significant limitations of current standard of care in controlling plasma arginine levels Topline safe...

Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics Abstracts illustrate the drivers and progression of ARG1-D including the long-term challenges faced by patients, caregivers and heal...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021 PR Newswire AUSTIN, Texas , Sept. 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of hu...

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...

Aeglea BioTherapeutics (NASDAQ:AGLE): Q2 GAAP EPS of -$0.10. As of June 30, 2021, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $130.4 million inclusive of the $21.5 million upfront cash payment received from Immedica Pharma AB pursuant to the March...

Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights Initiated Dosing in Phase 1/2 Clinical Trial of AGLE-177 in Homocystinuria Strengthened Leadership Team with Key Appointments, Including Jonathan Alspaugh as Chief Financial Officer...

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease PR Newswire AUSTIN, Texas , July 14, 2021 /PRNe...

Aeglea BioTherapeutics (AGLE) announces the appointment of Jonathan Alspaugh as the company's chief financial officer.Alspaugh has over a decade of experience advising healthcare companies on strategic and financial matters. He joins Aeglea from Evercore where he most...

Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer PR Newswire AUSTIN, Texas , July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human ...